Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.59 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.59 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3816087 | 1.00 | CYP3A4 (0.62) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL17832971 | 1.00 | CYP3A4 (0.62) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL3816790 | 1.00 | CYP3A4 (0.62) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL3820886 | 1.00 | CYP3A4 (0.62) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL11354446 | 1.00 | CYP3A4 (0.62) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL1726269 | 1.00 | CYP3A4 (0.62) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL3822908 | 1.00 | CYP3A4 (0.62) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL3819970 | 1.00 | CYP3A4 (0.62) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL3821561 | 1.00 | CYP3A4 (0.62) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL18347133 | 1.00 | CYP3A4 (0.62) | CYP3A4LPAR3LPAR2LPAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058768-A1 | MEMBRANE FOR WATER FILTRATION | AQUAPORIN A/S (DK) | 2024-02-22 | — | — | US | disclosed |
| EP-4277731-A1 | MEMBRANE FOR WATER FILTRATION | Aquaporin A/S (DK) | 2023-11-22 | — | — | EP | disclosed |
| CN-116745025-A | membrane for water filtration | 水通道蛋白有限公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2022152748-A1 | MEMBRANE FOR WATER FILTRATION | AQUAPORIN A/S (DK) | 2022-07-21 | — | — | WO | disclosed |
| US-20130259916-A1 | BACTERICIDAL SILVER SURFACTANT DELIVERY INTO COATING AND POLYMER COMPOSITIONS | EASTERN MICHIGAN UNIVERSITY (US) | 2013-10-03 | — | — | US | disclosed |
| EP-1276551-B1 | COMPOSITE MEMBRANE AND METHOD FOR MAKING THE SAME | DOW GLOBAL TECHNOLOGIES INC (US) | 2009-08-19 | — | — | EP | disclosed |
| US-6878278-B2 | Composite membrane and method for making the same | DOW GLOBAL TECHNOLOGIES INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-6723241-B2 | COMPRISING A POLYAMIDE LAYER ON A POROUS SUPPORT WHERE THE POLYAMIDE LAYER IS COMPLEXED OR HYDROGEN BONDED TO A PHOSPHORUS-CONTAINING COMPOUND; IMPROVED FLUX AND/OR REJECTION RATE; FILTERS; NANOFILTRATION AND REVERSE OSMOSIS | DOW GLOBAL TECHNOLOGIES INC. | 2004-04-20 | — | — | US | disclosed |
| US-20030116498-A1 | Composite membrane and method for making the same | THE DOW CHEMICAL COMPANY | 2003-06-26 | — | — | US | disclosed |
| US-6562266-B2 | Composite membrane and method for making the same | DOW GLOBAL TECHNOLOGIES INC. | 2003-05-13 | — | — | US | disclosed |
| EP-1276551-A2 | COMPOSITE MEMBRANE AND METHOD FOR MAKING THE SAME | DOW GLOBAL TECHNOLOGIES INC. (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20020113008-A1 | Composite membrane and method for making the same | THE DOW CHEMICAL COMPANY | 2002-08-22 | — | — | US | disclosed |
| US-6337018-B1 | COATING POROUS SUPPORT WITH SOLUTION OF POLYFUNCTIONAL AMINE AND SOLUTION OF POLYFUNCTIONAL ACYL HALIDE WHICH REACT TO FORM POLYAMIDE LAYER, INCLUDING STEP OF CONTACTING PHOSPHOROUS COMPOUND WITH ACYL HALIDE BEFORE REACTING WITH AMINE | THE DOW CHEMICAL COMPANY | 2002-01-08 | — | — | US | disclosed |
| US-20010050252-A1 | Composite membrane and method for making the same | DOW GLOBAL TECHNOLOGIES LLC | 2001-12-13 | — | — | US | disclosed |
| WO-2001078882-A2 | COMPOSITE MEMBRANE AND METHOD FOR MAKING THE SAME | DOW GLOBAL TECHNOLOGIES INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130259916-A1 | BACTERICIDAL SILVER SURFACTANT DELIVERY INTO COATING AND POLYMER COMPOSITIONS | CAPG, CLTB, DSTN | CYP3A4 4351/4885LPAR3 2614/4885LPAR2 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.